Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience Data show TEV-'749 drug delivery technology ...
Beyond the SOLARIS study, Teva presented results from in vitro studies that evaluated TEV-'749 against the currently marketed intramuscular olanzapine long-acting injectable for the risk of PDSS, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results